Page - (000261) - in Biomedical Chemistry: Current Trends and Developments

Bundgaard, H.; Moss, J. (1989). Prodrugs of peptides IV: Bioreversible derivatization of the pyroglutamyl group by N-acylation and N-aminomethylation to effect protection against pyroglutamyl aminopeptidase. Journal of Pharmaceutical Sciences, 78, 122-126. Burnette, T. C.; Harrington, J. A.; Reardon, J. E.; Merrill, B. M.; Miranda, P. (1995). Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. Journal of Biological Chemistry, 270, 15827-15831. Bruckdorfer, T.; Marder, O.; Albericio, F. (2004). From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Current Pharmaceutical Biotechnology, 5, 29-43. Bruston, F.; Lacombe, C.; Zimmermann, K.; Piesse, C.; Nicolas, P.; El Amri, C. (2007). Structural malleability of plasticins: preorganized conformations in solution and relevance for antimicrobial activity. Biopolymers, 86, 42-56. Cao, F.; Jinghao, J.; Yin, Z.; Gao, Y.; Sha, L.; Lai, Y.; Ping, Q.; Zhang, Y. (2012). Ethylene glycol- linked amino acid diester prodrugs of oleanolic acid for PepT1-mediated transport: tynthesis, intestinal permeability and pharmacokinetics. Molecular Pharmaceutics, 9, 2127- 2135. Carlsson, A.; Engstrom, P.; Palva, E. T.; Bennich, H. (1991). Attacin, an antibacterial protein from Hyalophora cecropia, inhibits synthesis of outer membrane proteins in Escherichia coli by interfering with omp gene transcription. Infection and Immunity, 59, 3040-3045. Carlsson, A.; Nystrom, T.; de Cock, H.; Bennich, H. (1998). Attacin - an insect immune protein- binds lps and triggers the specific inhibition of bacterial outer-membrane protein synthesis. Microbiology, 144, 2179-2188. Castle, M.; Nazarian, A.; Yi, S. S.; Tempst, P. (1999). Lethal effects of apidaecin on Escherichia coli involve sequential molecular interactions with diverse targets. Journal of Biological Chemistry, 274, 32555-32564. Cha, C.; Liechty, W. B.; Khademhosseini, A.; Peppas, N. A. (2012). Designing biomaterials to direct stem cell fate. ACS Nano, 6, 9353-9358. Chaloin, L.; Vidal, P.; Lory, P.; Mery, J.; Lautredou, N.; Divita, G.; Heitz, F. (1998). Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties. Biochemical and Biophysical Communications, 243, 601-608. Chan, G.; Mooney, D. J. (2008). New materials for tissue engineering: towards greater control over the biological response. Trends in Biotechnology, 26, 382-392. Chan, O. H.; Schmid, H. L.; Stilgenbauer, L. A.; Howson, W.; Horwell, D. C.; Stewart, B. H. (1998). Evaluation of a targeted prodrug strategy of enhance oral absorption of poorly water-soluble compounds. Pharmaceutical Research, 15, 1012-1018. Chambel, P.; Capela, R.; Lopes, F.; Iley, J.; Morais, J.; Gouveia, L.; Gomes, J. R. G.; Gomes, P.; Moreira, R. (2006). Reactivity of imidazolidin-4-one derivatives of primaquine: implications for prodrug design. Tetrahedron, 62, 9883-9891. Chau, Y.; Tan, F. E.; Langer, R. (2004). Synthesis and Characterization of Dextran−Peptide −Methotrexate Conjugates for Tumor Targeting via Mediation by Matrix Metalloproteinase II and Matrix Metalloproteinase IX. Bioconjugate Chemistry, 15, 931-941. Christensen, B.; Flink, J.; Merrifield, R. B.; Mauzerall, D. (1988). Channel-forming properties of cecropins and related model compounds incorporated into planar lipid membranes. Proceedings of the National Academy of Sciences of USA, 85, 5072-5076.